PMID- 27522390
OWN - NLM
STAT- MEDLINE
DCOM- 20171003
LR  - 20181202
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 222
DP  - 2016 Nov 1
TI  - Cardioprotective effect of atorvastatin alone or in combination with remote 
      ischemic preconditioning on the biochemical changes induced by 
      ischemic/reperfusion injury in a mutual prospective study with a clinical and 
      experimental animal arm.
PG  - 866-873
LID - S0167-5273(16)31571-6 [pii]
LID - 10.1016/j.ijcard.2016.07.178 [doi]
AB  - BACKGROUND: Atorvastatin and remote ischemic preconditioning (RIPC) have 
      beneficial cardiovascular protective effects. The aim of the study was to 
      investigate possible effect of this drug alone and in combination with RIPC on 
      the biochemical changes induced by ischemic/reperfusion injury (I/R) in a 
      combined study with a clinical and experimental animal arm. METHODS: Thirty 
      consecutive patients undergoing elective percutaneous coronary intervention (PCI) 
      were divided into three groups (10 each): group I (control group without any 
      preconditioning), group II (patients who were maintained on atorvastatin 
      (80mg/day) for one month before PCI), and group III (similar to group II but PCI 
      was preceded by RIPC). On the other hand, sixty adult male New Zealand white 
      rabbits were divided into 6 groups (10 each): group I (control), group II (sham), 
      group III (I/R as 30min ischemia followed by 120min reperfusion), group IV 
      (regular atorvastatin 10mg/kg for 40days orally followed by I/R), group V (I/R 
      preceded by RIPC) and group VI (similar to group IV but I/R was preceded by 
      RIPC). Tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), nitric oxide (NO), 
      troponin I (cTnI), creatine kinase MB (CK-MB) and C-reactive protein (CRP) were 
      measured in blood for all study groups. RESULTS: Clinical and experimental parts 
      showed that groups with RIPC combined with atorvastatin pre-treatment showed a 
      synergistic protective effect against I/R injury as evidenced by significant 
      reduction (P<0.001) in the levels of TNF-alpha, cTnI (in patients) and IL-6, CK-MB 
      and CRP (in rabbits) while the level of NO was significantly (P<0.001) increased 
      compared with other groups. CONCLUSIONS: Pretreatment with atorvastatin combined 
      with RIPC can exert a synergistic cardioprotective effects by reducing the 
      possible biochemical changes related to ischemic reperfusion injury.
CI  - Copyright (c) 2016. Published by Elsevier Ireland Ltd.
FAU - El Desoky, Ehab S
AU  - El Desoky ES
AD  - Pharmacology Department, Faculty of Medicine and University Hospital, Assiut 
      University, Assiut. Egypt.
FAU - Hassan, Ayman K M
AU  - Hassan AKM
AD  - Cardiology Department, Faculty of Medicine and University Hospital, Assiut 
      University, Assiut. Egypt. Electronic address: aymankhairy11@gmail.com.
FAU - Salem, Safaa Y
AU  - Salem SY
AD  - Pharmacology Department, Faculty of Medicine and University Hospital, Assiut 
      University, Assiut. Egypt.
FAU - Fadil, Sabah A
AU  - Fadil SA
AD  - Pathology Department, Faculty of Medicine and University Hospital, Assiut 
      University, Assiut. Egypt.
FAU - Taha, Amira F
AU  - Taha AF
AD  - Pharmacology Department, Faculty of Medicine and University Hospital, Assiut 
      University, Assiut. Egypt.
LA  - eng
PT  - Journal Article
DEP - 20160729
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Biomarkers)
RN  - 0 (Cytokines)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - A0JWA85V8F (Atorvastatin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Animals
MH  - Atorvastatin/*therapeutic use
MH  - Biomarkers/blood
MH  - C-Reactive Protein/metabolism
MH  - Cytokines/blood
MH  - Disease Models, Animal
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Ischemic Preconditioning/*methods
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/prevention & control
MH  - Myocardial Reperfusion Injury/blood/*prevention & control
MH  - Nitric Oxide/blood
MH  - Prospective Studies
MH  - Rabbits
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - Atorvastatin
OT  - Biochemical markers
OT  - Ischemic reperfusion
OT  - Remote ischemic reperfusion
EDAT- 2016/08/16 06:00
MHDA- 2017/10/04 06:00
CRDT- 2016/08/15 06:00
PHST- 2016/06/05 00:00 [received]
PHST- 2016/07/27 00:00 [accepted]
PHST- 2016/08/15 06:00 [entrez]
PHST- 2016/08/16 06:00 [pubmed]
PHST- 2017/10/04 06:00 [medline]
AID - S0167-5273(16)31571-6 [pii]
AID - 10.1016/j.ijcard.2016.07.178 [doi]
PST - ppublish
SO  - Int J Cardiol. 2016 Nov 1;222:866-873. doi: 10.1016/j.ijcard.2016.07.178. Epub 
      2016 Jul 29.